Shilpa Medicare’s arm files first drug master file of Recombinant Human Albumin 20%

04 Jun 2024 Evaluate

Shilpa Medicare’s wholly owned subsidiary -- Shilpa Biologicals has filed its first Drug Master File of Recombinant Human Albumin 20% with United States Food and Drug Administration (USFDA). This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process which is completely-Environment friendly, Consistent High-Quality product, Scalable to massive scales and is cost competitive. Recombinant Human Albumin 20% targets to fulfil growing demand of human serum albumin to deliver current and growing market demand.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.


Shilpa Medicare Share Price

289.95 -2.95 (-1.01%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×